NCT01012492 · REGISTRY CONDITION SEARCH

Pilot of Abatacept-based Immunosuppression for Prevention of Acute GvHD During Unrelated Donor HCT

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2019-11-21

The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Percentage of Participants With Grade III-IV Acute GVHD by Day 100.

→

outcome · POSTED

Percentage of Participants With Grades III-IV Acute GVHD at 2 Years

→

outcome · POSTED

Hematologic and Immunologic Reconstitution

→

outcome · POSTED

Protective Immunity

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: 1. Patients with AML, with or without a history of myelodysplastic syndrome in one of the following categories. (a) Patients in first complete remission with high-risk features 2. Patients with ALL, in either of the following categories: 1. In 2nd or greater complete remission (complete remission is defined as \> 5% blasts in marrow) 2. Delayed 1st CR-Failure to achieve complete remission after a single round of induction therapy 3. Patients with undifferentiated or biphenotypic leukemia in 1st or greater complete remission. 4. Patients with Myelodysplastic Syndrome(s) with an IPSS score of \>1.5 and \<10% blasts in the bone marrow at the time of transplant. These conditions will include: 1. Refractory anemia 2. Refractory anemia with ringed sideroblasts 3. Refractory cytopenia with multilineage dysplasia 4. Refractory cytopenia with multilineage dysplasia and ringed sideroblasts 5. Refractory anemia with excess blasts-1 (5-10% blasts) 6. Refractory anemia with excess blasts-2 (10-20% blasts) 7. Myelodysplastic syndrome, unclassified 8. MDS associated with isolated del (5q) 9. Patients diagnosed with AML in CR1 after an initial diagnosis of MDS. 5. Age 12 years or older. 6. No prior allogeneic transplant 7. Karnofsky performance score or Lansky Play-Performance of at least 80. 8. Signed informed consent for adults and for minors the provision of pediatric assent and parental permission. Exclusion Criteria: 1. Age \<12 years old. 2. Patients requiring \>2 courses of induction chemotherapy to achieve remission status. 3. HIV infection 4. Tuberculosis Infection 5. Chronic Obstructive Pulmonary Disease 6. Pregnancy (positive serum b-HCG) or breastfeeding 7. Creatinine clearance or nuclear medicine GFR of \< 50 mL/min 8. Cardiac ejection fraction \< 50% 9. bilirubin \> 2 × upper limit of normal or ALT \> 4 × upper limit of normal or unresolved veno-occlusive disease. 10. Pulmonary disease with FVC, FEV1 or DLCO parameters \<45% predicted (corrected for hemoglobin) or O2 saturation \<92% on room air. 11. Karnofsky performance score or Lansky Play-Performance Scale \<80 12. Uncontrolled viral, bacterial, or fungal infection at the time of study enrollment 13. Availability of a willing and fully MHC-matched related donor. 14. Positive cytotoxic recipient-donor cross-match or positive HLA antibody screen against donor-disparate antigens. 15. Any active infection. 16. Unable to obtain informed consent.
healthy Volunteers: false
minimum Age: 12 Years
sex: ALL
std Ages: CHILD
ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
intervention Names
Drug: Abatacept
label
Abatacept
type
EXPERIMENTAL

interventions

arm Group Labels
Abatacept
description
Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
name
Abatacept
other Names
orencia
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 11
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

description
Grade III-IV Acute GVHD by Day 100. The incidence of Gr III-IV acute GVHD was measured by the modified Glucksburg scale.
measure
Percentage of Participants With Grade III-IV Acute GVHD by Day 100.
time Frame
Day 100 post-transplant

secondary Outcomes

description
The rates of Grades III-IV acute GVHD were measured at 2 years according to standard Glucksberg criteria, which was 10%.
measure
Percentage of Participants With Grades III-IV Acute GVHD at 2 Years
time Frame
2 years after transplant
description
Flow cytometric analysis of CD4 t-cell t-cell reconstitution was performed at day +100 post-transplant.
measure
Hematologic and Immunologic Reconstitution
time Frame
Day +100 post-transplant
description
Percent of CMV virus binding CD8+ t-cells at day +365 post-transplant
measure
Protective Immunity
time Frame
Day +365 post-transplant

Full study description

brief Summary: The primary objective of the study is to determine the safety and tolerability when adding abatacept to acute Graft versus Host Disease in transplants for malignant diseases using unrelated donor bone marrow or peripheral blood stem cell grafts.
detailed Description: Acute Graft versus Host Disease (aGvHD) is the most deadly complication facing children who have allogeneic hematopoietic stem cell transplant (HSCT). aGvHD occurs, in large part, because the T cells in the bone marrow graft do not "accept" the presence of the transplant recipient's cells, and mount a severe, debilitating, and often deadly attack against the recipient, striking the skin, the liver, and the gastrointestinal track, most prominently. For patients receiving bone marrow from an unrelated donor, the rate of aGvHD can reach as high as 80%, with up to half of patients dying from this complication. These serious outcomes occur despite our best efforts at aGvHD prevention. Given the lack of success in preventing aGvHD with current therapies, novel therapies to prevent this disease are desperately needed. In this study, we plan to test a novel drug to prevent aGvHD. This drug, known as abatacept, specifically blocks the activation pathway critical to T cell function known as "T cell costimulation." In particular, it blocks the CD28-mediated costimulation pathway that is critical for optimal T cell activation and proliferation. My research group has done extensive pre-clinical work with this compound. Our work has demonstrated its efficacy in inducing immune tolerance after transplantation in both mouse models and primate models. In addition, patient trials have demonstrated that blocking CD28-directed T cell costimulation can prevent T cell-mediated diseases, including rheumatoid arthritis and psoriasis, and can improve solid organ transplant acceptance. Abatacept is currently FDA approved for use in rheumatoid arthritis. Given this drug's safety and efficacy profile, we have been granted an IND-exemption from the FDA for the inclusion of abatacept in a GvHD-prevention strategy. This is a safety and tolerability study of the addition of abatacept to a GvHD-prophylaxis regimen. Thus, the primary objective of the study is to determine the safety and tolerability of the addition of abatacept to aGvHD prophylaxis in transplants for malignant hematologic disease using unrelated donor bone marrow or peripheral blood stem cell grafts. Three secondary objectives will also be addressed: 1. We will estimate the incidence and severity of aGvHD in patients receiving the abatacept-based protocol. 2. We will determine the immune phenotype of donor cells in patients receiving abatacept. 3. We will determine the ability of donor T-cells in patients receiving abatacept to respond to both polyclonal and recipient-specific immune stimulation. These secondary objectives will allow us to determine the impact of abatacept-containing GvHD prevention on both T cell alloreactivity and on T cell-mediated protective immunity. This study is for patients older than 12 who have been diagnosed with high-risk leukemia and for whom an unrelated bone marrow transplant is planned. We plan to enroll 10 patients on the study, over a 1-year period from the opening of the trial. Of these ten patients, at least five will be pediatric patients; the other five may be from adult patients taken care of by Winship Cancer Center physicians. All clinical study coordination and biologic studies will be performed by CHOA personnel. Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept. They will have immunologic analysis for 1 year after transplant and clinical analysis for 3 years after transplant.

Source references

references

citation
Koura DT, Horan JT, Langston AA, Qayed M, Mehta A, Khoury HJ, Harvey RD, Suessmuth Y, Couture C, Carr J, Grizzle A, Johnson HR, Cheeseman JA, Conger JA, Robertson J, Stempora L, Johnson BE, Garrett A, Kirk AD, Larsen CP, Waller EK, Kean LS. In vivo T cell costimulation blockade with abatacept for acute graft-versus-host disease prevention: a first-in-disease trial. Biol Blood Marrow Transplant. 2013 Nov;19(11):1638-49. doi: 10.1016/j.bbmt.2013.09.003. Epub 2013 Sep 15.
pmid
24047754
type
RESULT
citation
Suessmuth Y, Mukherjee R, Watkins B, Koura DT, Finstermeier K, Desmarais C, Stempora L, Horan JT, Langston A, Qayed M, Khoury HJ, Grizzle A, Cheeseman JA, Conger JA, Robertson J, Garrett A, Kirk AD, Waller EK, Blazar BR, Mehta AK, Robins HS, Kean LS. CMV reactivation drives posttransplant T-cell reconstitution and results in defects in the underlying TCRbeta repertoire. Blood. 2015 Jun 18;125(25):3835-50. doi: 10.1182/blood-2015-03-631853. Epub 2015 Apr 7.
pmid
25852054
type
RESULT

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-62726ea9d0fe59297636
requested nct id
NCT01012492
primary nct id
NCT01012492
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
payload sha256
6aaf233fbefdd9e0bbb04233298f1375e3757cd8c46d04c4258f1061f7fe9a78
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-62726ea9d0fe59297636
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT01012492
occurrences
context exact
NCT01012492
end
11
exact text
NCT01012492
start
0
offset unit
unicode_code_points
query cond
Acute Undifferentiated Leukemia
query disease state id
ds-acute-undifferentiated-leukemia
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-acute-undifferentiated-leukemia-000.json
source file sha256
a6089e8b15d43633ec778b2a5c464ada1207289beea2ae90de3e4bbe04b32186
source json pointer
/studies/8/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
8299a23bb53b74f35adcc0e13966dec077df62f47e25535fa56febd40bb92ecd
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Acute+Undifferentiated+Leukemia&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice